Abstract | OBJECTIVES: METHODS: A prospective multi-center partly randomized control trial was conducted in patients with mild acute pancreatitis (AP). Nonobese patients received conventional management (nonobese-C, n = 82), whereas obese patients (body mass index ≥ 25 kg/m(2)) were randomized into 2 groups: obese-C (n = 79), who received conventional management, and obese-C+O (n = 82), who received conventional management plus intravenous infusion of octreotide, 50 μg/h for 72 hours. RESULTS: The risk ratio and relative risk reduction in the development of SAP in the obese-C+O group were 0.27 (95% confidence interval, 0.10-0.69) and 0.73 (95% confidence interval, 0.31-0.90), respectively. The number of cases developing local complications in the obese-C+O group was significantly smaller than that in the obese-C group: 4.9% vs 19%, P = 0.006. The plasma level of somatostatin in the obese-C+O group was significantly higher than that in the obese-C group: 165.5 ± 42.6 vs 112.1 ± 24.86 pg/mL, P < 0.05. Supplement of octreotide also accompanied with reduction in plasma levels of tumor necrosis factor α and IL-6. CONCLUSIONS:
|
Authors | Fan Yang, Hao Wu, Yanqing Li, Zhaoshen Li, Chunhui Wang, Jinlin Yang, Bing Hu, Zhiyin Huang, Rui Ji, Xianbao Zhan, Huizhong Xie, Lei Wang, Mingguang Zhang, Chengwei Tang |
Journal | Pancreas
(Pancreas)
Vol. 41
Issue 8
Pg. 1206-12
(Nov 2012)
ISSN: 1536-4828 [Electronic] United States |
PMID | 23086244
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gastrointestinal Agents
- Interleukin-6
- Tumor Necrosis Factor-alpha
- Somatostatin
- Octreotide
|
Topics |
- Adult
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Interleukin-6
(blood)
- Male
- Middle Aged
- Obesity
(complications)
- Octreotide
(therapeutic use)
- Pancreatitis
(drug therapy, prevention & control)
- Severity of Illness Index
- Somatostatin
(blood)
- Tumor Necrosis Factor-alpha
(blood)
|